ReviewJournal of transplantation2026
Belatacept and the Risk of Cytomegalovirus, BK Polyomavirus, and Epstein-Barr Virus Post-transplant Lymphoproliferative Disease After Kidney Transplantation: A Meta-Analysis and Systematic Review.
Review in Journal of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The long-term risk of cytomegalovirus (CMV), Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), and BK viral infections from belatacept is unclear. This review aimed to evaluate these outcomes. Methods: Several databases were reviewed from inception through September 2025 using the keywords "belatacept" and "kidney transplant" or "safety" and "viral infection". We included case reports, randomized controlled trials (RCTs), and nonrandomized trials (NRTs). Outcomes were prespecified according to dose (more-intense or less-intense), type of infection (CMV, EBV-PTLD, or BK), and follow-up period: short term (1-2 years), medium term (3-5 years), and long-term (> 5 years). RCTs and NRTs were analyzed separately, and case reports were summarized. For binary outcomes, results were presented as risk ratios (RR), with 95% confidence intervals (CI). All statistical analyses were performed using Revman 5.2. Results: Sixty-four studies (23 RCTs, 28 NRTs, and 13 case reports) were included. Of 23 RCTs, 11 were primary studies while the remainder were follow-up reports of original RCTs. Most NRTs (16/28) included a comparator arm. In the meta-analyses of RCTs only, the risks of CMV, EBV-PTLD, and BK virus infection were similar between patients receiving belatacept and those receiving calcineurin inhibitors (CNIs). During medium-term follow-up for RCTs, BK virus infection was twice as likely among those receiving more-intense compared to less-intense belatacept (RR: 2.08 [CI 1.03, 4.20, Conclusions: The risks of CMV and EBV-PTLD after kidney transplantation were not significantly increased by belatacept based on RCTs, though a higher risk of BK polyomavirus infection was observed among patients receiving a more-intense dose of belatacept beyond the second year. The risk of CMV and BK polyomavirus infections may also be increased with real-world belatacept use. However, these observations should be interpreted with consideration for the inherent limitations of NRTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.